Drug Profile
TAK 195
Alternative Names: Sabin-inactivated poliovirus vaccine - Takeda; Sabin-IPV - Takeda; sIPV - Takeda; TAK-195Latest Information Update: 18 Jul 2019
Price :
$50
*
At a glance
- Originator Takeda
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Poliomyelitis
Most Recent Events
- 18 Oct 2018 Suspended - Phase-I/II for Poliomyelitis (In adolescents, In children, In infants, Prevention, In adults) in Panama (IM) (NCT03092791)
- 18 Oct 2018 Takeda terminates a phase I/II trial in Poliomyelitis (In adults, In children, Prevention, In infants, In adolscents) in Panama due to planned immunogenicity outcomes not reached (NCT03092791)
- 07 Jun 2017 Phase-I/II clinical trials in Poliomyelitis (Prevention, In children, In infants, In adolescents, In adults) in Panama (IM) (NCT03092791)